What Biotech Licensing Really Buys

Biotech licensing is often viewed as a transaction centered on intellectual property. However, it's crucial to understand that the molecule is not the only asset involved. The development system built around the molecule, including cell line history, process development logic, analytical methods, comparability strategy, manufacturing experience, documentation discipline, and technical judgment, also forms a significant part of the asset.

Licensing agreements can specify rights to these assets and the obligations surrounding their transfer, but they cannot guarantee that the development system will remain reproducible in another organization. Despite initial appearances of de-risking, the asset can carry technical liabilities that emerge during transfer, scale-up, validation, or regulatory review.

These liabilities often manifest in subtle forms that can be easily dismissed during the excitement of dealmaking, such as when a potency assay performs consistently in the originating laboratory but shows unexplained variability later due to differences in laboratory conditions or system suitability behavior. Similarly, while a comparability strategy may exist on paper, its effectiveness can be undermined by process changes.

These issues can remain hidden until another organization has to reproduce the process or defend the analytics, making them particularly dangerous. The problem is further exacerbated by organizational incentives that can delay addressing these issues. After signing, the seller may close the deal, while the technical teams on both sides may still be figuring out the transfer of knowledge, responsibilities, and decisions.

These transfer problems can become increasingly costly to resolve as they become visible. The language of licensing can be misleading in biologics because intellectual property can be precisely assigned, but process knowledge, development judgment, and technical context do not transfer as smoothly. While a contract can define rights, territories, and economics, it cannot ensure the transfer of tacit knowledge reflected in assay behavior, deviation history, control strategy logic, and other small decisions.

The critical knowledge that determines reproducibility is often held by a few people within an organization, such as the scientist who characterized the founding cell line or the process development lead who resolved early instability. This knowledge is rarely captured in a batch record. Therefore, the question should not be about the amount of documentation, but rather about how much of the knowledge required to interpret that documentation can actually travel.